Phase 2 Hearing Loss Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with advanced non-small cell lung cancer (NSCLC) that cannot be removed by surgery or has spread to other parts of the body, confirmed by a lab test on a tissue sample
- You are willing to provide a sample of your tumor tissue as required by the trial
- Your cancer has been shown to have a specific change (alteration) in a gene called MET
- You are generally able to carry out daily activities with little or no limitation (confirm with trial site what level of ability is required)
- Your organs (such as kidneys and liver) and bone marrow are working well enough as measured by blood tests
Who may not be able to join:
- You have received an approved cancer treatment or taken part in another experimental drug study within the last 2 weeks
- You are still experiencing significant side effects from a previous cancer treatment that have not yet gone away
- You have had radiation therapy or major surgery within the last 14 days
- You have a brain tumor, cancer that has spread to the brain or spinal fluid, or spinal cord compression that has not been treated or is currently active (confirm with trial site for specific details)
- You currently have an infection that is not under control
Important: Always verify eligibility with the trial site directly before applying.
Note: This is a summary of the main criteria only. Additional requirements exist — the trial team will review your full medical history to confirm whether you qualify.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trial Management, Regeneron Pharmaceuticals
Phone: 844-734-6643
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of patients with Dose Limiting Toxicities (DLTs); Incidence and severity of treatment-emergent adverse events (TEAEs); Incidence and severity of adverse events of special interest (AESIs); Incidence and severity of serious adverse events (SAEs); Incidence and severity of grade ≥3 laboratory abnormalities; REGN5093 concentrations in serum over time; Objective response rate (ORR) per RECIST 1.1
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.